Liraglutide clinical trials. Clinical trials report HbA1c reductions of about −0.

Liraglutide clinical trials Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial This trial is registered on Clinicaltrials. Four of these are part of the Satiety Satiety and Clinical Adiposity—Liraglutide Evidence (SCALE) Insulin was a 56-week, randomized, double-blind, placebo-controlled, multinational, multicenter trial in individuals with overweight or obesity and In this randomized, double-blind trial, which consisted of a 56-week treatment period and a 26-week follow-up period, we enrolled In clinical trials, liraglutide has proven to be an effective drug for the treatment of type 2 diabetes mellitus (T2DM). Liraglutide is a glucagon-like peptide-1 (GLP-1) analogue that has shown The data from clinical trials on WL with liraglutide 3 mg are robust, but its clinical effectiveness in SWMS settings has not been assessed. Clinical trials report HbA1c reductions of about −0. Alzheimer’s disease is a leading cause of morbidity worldwide. , Citation 2023; Peters, Citation 2010). The real-world effectiveness of liraglutide has been investigated in numerous studies. This article examines the use of liraglutide, marketed as Saxenda® and Victoza®, in various clinical trials. 50) . 4 mg, vs once-daily subcutaneous liraglutide, 3. 2 pounds) in those taking a placebo. 3. Liraglutide is a glucagon like peptide-1 (GLP-1) receptor agonist, marketed as Saxenda® and Victoza®. The aim of this systematic literature We aimed to evaluate the effects of injectable liraglutide 3·0 mg daily on body fat distribution in adults with overweight or obesity without type 2 diabetes at high cardiovascular disease risk. 8%, compared to 6. In this double-blind, placebo-controlled, parallel arm pilot study, overweight and obese smokers (N=40; 20 female and 20 male) will be randomized to 32 weeks of liraglutide or placebo and undergo 8 A Phase I Clinical Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single Doses of 4P004 Versus Placebo Injected in the Target Knee of Patients With Grade 2 to 4 Osteoarthritis on the Kellgren and Lawrence Severity Index Plasma concentration of liraglutide following a single IA injection at pre-injection (Time [-4hours-0 Study question: What are the effects of liraglutide, an incretin based treatment, on glycaemic control in people with type 2 diabetes treated with multiple daily insulin injections? Methods: The study was a randomised, double blind, placebo controlled trial with a parallel group design carried out at 13 hospital based outpatient clinics and one primary care unit in Sweden. It is also approved at a higher dose for the treatment of obesity (3,4). The results of this trial were generally consistent with previous semaglutide and liraglutide trials. Obesity Liraglutide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures in both genders of rats and mice. The company is running two Phase 3 trials in people with MCI or mild AD. Design Systematic Skov, J, Pedersen, M, Holst, JJ, et al. FDA Status: Alzheimer's Disease (Phase 2), Parkinson's Disease (Phase 2) Company: Novo Nordisk A/S Approved for: Diabetes, weight loss Background. As a result, liraglutide (Saxenda®) was approved in the United States and Europe as an adjunct to a Of the 835 randomized subjects, 832 were exposed to liraglutide or placebo in addition to insulin during the trial (liraglutide 0. The study was done in eight countries involving 71 clinical sites. Trials with a crossover design, non-inferiority studies comparing GLP-1RA and other drug classes without a placebo Overview. Name: Liraglutide Synonyms: Victoza™, Saxenda™ Therapy Type: Other Target Type: Other Condition(s): Alzheimer's Disease, Parkinson's Disease U. 8 years with liraglutide or placebo once daily. glimepiride and sitagliptin). Liraglutide is a glucagon-like peptide 1 receptor agonist (GLP-1 RA) approved for the management of hyperglycemia in type 2 diabetes and for reduction of cardiovascular (CV) risk in patients with type 2 diabetes and clinical CV disease (CVD) (1,2). 17. Short-term effects of liraglutide on kidney function and vasoactive hormones in type 2 diabetes: a randomized clinical trial. 001). 1 Pharmacology and Clinical Pharmacokinetics . CT. Objective: To assess the efficacy and safety of the GLP-1 receptor agonist, liraglutide, 3. If the ELAD trial is successful, liraglutide and GLP-1 analogues will represent an important class of compounds to be further evaluated in clinical trials for Alzheimer’s Conclusions and relevance: In this randomized clinical trial of people with type 2 diabetes and PAD, liraglutide increased peripheral perfusion detected by TcPo2 measurement during 6 months of treatment. During AAIC 2024, Edison sat down to discuss the data, including the primary cognitive and neuroimaging outcomes observed among patients with AD treated with liraglutide. Menu. Clinical trial registration: DCTR: CTR20190914; ClinicalTrials. This clinical research trial examines the effects of the GLP-1 receptor agonist liraglutide on smoking behavior, food intake, and weight gain. 6 mg, n = 211; 1. 1001-6821. 001), and 33. This single center, double-blind, placebo-controlled study will enroll 57 participants with a diagnosis of idiopathic PD. 013 Well-positioned to test this further are current late-stage clinical trials of GLP-1 analogues, several of which are ongoing. Preclinical evidence in transgenic models of Alzheimer’s disease suggests that liraglutide exerts neuroprotective effects by reducing amyloid oligomers, normalising synaptic plasticity and cerebral glucose uptake, and increasing the proliferation of neuronal Once-Weekly Semaglutide Versus Once-Daily Liraglutide for Weight Loss in Adults: A Meta-Analysis of Randomized Controlled Trials and fasting glucose levels compared to once-daily liraglutide. Subscribe Subscribe The satiety effect of GLP-1 receptor agonists and documented weight loss as great as 3. Crossref. Food and As of 2020, liraglutide was the most widely prescribed medication for obesity treatment, encompassing greater than 56% of the global market share. The In clinical trials, semaglutide reduced peripheral inflammation and decreased the risk of major adverse cardiovascular (CV) events (MACE) compared with placebo [38,39 Semaglutide and liraglutide are structurally similar molecules The trial was designed using A'Hern's single-group method, which required eight (38%) of 21 successes in the liraglutide group for the effect of liraglutide to be considered clinically significant. Gastrointestinal adverse events (AEs), including transient events of nausea, diarrhea, and vomiting, were the most common AEs reported in liraglutide trials. Liraglutide, a GLP-1 receptor agonist, can lower blood sugar by increasing insulin production and inhibiting the production of glucagon. 3 %) subjects had low-level antibodies to liraglutide 1. Methods: In this randomized, double-blind trial, which consisted of a 56-week treatment period and a 26-week follow-up period, we enrolled adolescents (12 to <18 years of age) with obesity We included all perticipants from the Functional Impact of GLP-1 for Heart Failure Treatmen (FIGHT) [] and Effect of Liraglutide on Left Ventricular Function in Stable Chronic Heart Failure Patients with and without Diabetes (LIVE) [] trials, which are multicentre, double-blind, randomised, placebo-controlled clinical trial. It is clear from these results that GLP-1 receptor agonists not only protect the brain from PD-related disease progression, but also from AD related disease progression. 38 kg in clinical trials may make liraglutide ideal for obese patients with type 2 diabetes mellitus. 20 to 2. This site is intended for healthcare In clinical trials, liraglutide showed a placebo-corrected weight loss of around 5 %, semaglutide 12 %, and tirzepatide 18 %. liraglutide clinical trials - Systematic review and meta-analysis Author: TrialResults-center. Indeed, its use as part of a comprehensive approach has the potential to contribute to the effective Liraglutide is a once-daily human glucagon-like peptide-1 analogue used in the treatment of type 2 diabetes (T2D). Clinical trial of liraglutide injection combined with metformin tablets in the treatment of type 2 diabetes mellitus complicated with coronary heart disease Chin. Evaluating the Effects of the Novel GLP-1 Analogue, Liraglutide, in Patients With Mild Alzheimer's Disease (ELAD Study) This is a 12-month, multicentre randomised double-blind placebo-controlled Phase IIb study in patients with mild Alzheimer's dementia (AD). Subjects enrolled in the study will be randomized to receive once daily self-administered injections of liraglutide (1. The Satiety and Clinical Adiposity-Liraglutide Evidence (SCALE) clinical trial reported that 3. Common side effects were predominantly gastrointestinal, including nausea, diarrhea, constipation, and vomiting. 8 mg daily subcutaneous injection of liraglutide that was initially approved by the FDA in 2010 as an adjunct therapy to diet and exercise for management of type 2 diabetes 1. We randomly assigned participants (6:1) to each Few clinical trials have reported results with a GLP-1 receptor agonist in patients with type 2 diabetes and moderate renal impairment . 2077 - 2079 , 10. In addition The results of a Phase IIb clinical trial suggest that the glucagon-like peptide-1 (GLP-1) drug liraglutide (Novo Nordisk) may slow cognitive decline associated with Alzheimer disease (AD) by protecting against shrinkage in Tagged With: Alzheimer's treatment, clinical trials, cognitive impairment, insulin resistance, liraglutide, Novo Nordisk, semaglutide Related Articles Read More > A B-vitamin rescues Parkinson-like damage in flies, pointing to new neuroprotective strategy This review specifically addresses the Phase III clinical trials of the GLP-1 RA liraglutide. 2 or 1. 0 mg liraglutide had no significant association with the composite outcome of first occurrence of cardiovascular death, nonfatal myocardial infraction, or nonfatal stroke (hazard ratio, 0. 13699/j. 27 Given its widespread use, proven cardiometabolic benefit, and potential The trial was also limited by the long recruitment period (owing to problems inherent in clinical trials of youth with type 2 diabetes 2), which necessitated some protocol amendments. Rare serious adverse events included gallbladder disorders and acute pancreatitis. 70; 95% CI, 0. Methods: In this phase 3b, open-label trial, 577 adults with type 2 diabetes (HbA 1c 7. The starting dose of liraglutide was 0. As available treatments are only symptomatic, the search for disease-modifying therapies is a priority. 0 mg, on percentage body weight reduction in patients with poor Based on the available clinical trial evidence, liraglutide appears to be a promising treatment option for children and adolescents with obesity, demonstrating significant improvements in weight reduction, BMI, and metabolic parameters. Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial dose-ranging, phase 2 trial. 2 mg, Furthermore, the capped insulin dose is rarely used in clinical trials in subjects Semaglutide has higher efficacy than liraglutide. 0 mg (both with diet and physical activity), in people with overweight or obesity. Introduction. Both trials, which use change in Clinical Dementia Rating-Sum of Boxes score as the primary end point, are expected to have data read out in 2025. 6 mg/day every 7 days to reach the full dosage of 3 mg/day by week 5. 0-11. Eligible participants were adults (≥18 years) without diabetes and with a body-mass index (BMI) of 30 kg/m 2 or more. A small clinical trial suggests that drugs like Ozempic could potentially be used not just for diabetes and weight loss but to protect the brain, slowing the rate at which people with Alzheimer For example, EVOKE Plus is a 3-year clinical trial of semaglutide in more than 1,800 people with early Alzheimer’s disease. Patients, investigators, clinical trial site staff, and pathologists were masked to treatment assignment throughout the study. , 2015). , 34 ( 17 ) ( 2018 ) , pp. Results from an albiglutide active comparator-controlled which corresponds to the AE patterns observed in other liraglutide trials. Poor weight loss is associated with lower circulating levels of glucagon-like peptide-1 (GLP-1). 4 kg (about 18. Importance: Metabolic surgery leads to weight loss and improved health, but these outcomes are highly variable. 1. 2. The aim of this systematic literature The improvements in cognition in this trial confirm the cognitive improvements by exendin-4 and by liraglutide in the clinical trials in PD patients (see above). Approximately 8. EMBASE, and the Cochrane Library to search randomized clinical trials that examined body weight changes with liraglutide treatment. 7 %) and 49 of 587 (8. Body fat excess, particularly visceral fat accumulation, is another We would like to show you a description here but the site won’t allow us. 11, 14, 15 Based on a cost-effectiveness analysis, the National Institute for Health and The study was a phase III, randomized, open label, parallel group, two-arm study with assessor blinding to evaluate the efficacy, safety, and tolerability of Levim liraglutide as compared to reference liraglutide (Victoza) In clinical trials, liraglutide has proven to be an effective drug for the treatment of type 2 diabetes mellitus (T2DM). Clinical Trial NCT05444569; A Study of LY3537021 in Healthy Participants February 28, (GLP-1) receptor agonist called liraglutide in treatment-naïve healthy participants. Primary outcomes We did a randomised, double-blind, placebo and active controlled, multicentre, dose-ranging, phase 2 trial. 1% and 10. 0mg) with the current most frequently prescribed liraglutide dose in Europe (1. 1% in the placebo group lost at least 5% of their body weight (P<0. The study will include 2 parts. Liraglutide is a recently developed analog of the human incretin hormone GLP-1 that is representative of the GLP-1 RA class and which has been tested in a wide patient population. Efficacy and tolerability findings from the Liraglutide Trial ID: EX2211-3748 Protocol EudraCT No. The most frequently reported adverse events with liraglutide were mild or moderate nausea and diarrhea. 6%, respectively, lost more than 10% of their body weight (P<0. An extensive phase 3 clinical trial programme was completed to evaluate the efficacy and safety of liraglutide treatment, both as a monotherapy and in combination with selected oral antidiabetic drugs (OADs); data from these trials support liraglutide approval in Europe, Japan, Mexico and For example, EVOKE Plus is a 3-year clinical trial of semaglutide in more than 1,800 people with early Alzheimer's disease. Liraglutide is a powerful GLP-1 agonist, used in diabetes and obesity treatment. 8 mg, as tolerated) or placebo in a 2:1 study design for 52 weeks after titration. 2% and weight loss of 5–6 kg over 26–52 weeks. , 2015; Pi-Sunyer et al. Results: We included 31 studies with 8,060 participants for this meta In five clinical trials of 26 weeks or longer (US Food and Drug Administration, 2017), approximately 50%–70% of Victoza-treated patients were tested for anti-liraglutide antibodies at the end of treatment. Liraglutide was studied in this program alone or in combination therapy with other antidiabetic drugs. Trial Background. Participants remained enrolled in the trial if the use of liraglutide or placebo was discontinued a randomized clinical trial. However, with the cardioprotective benefit of liraglutide evident in first MACE and total MACE, the question arises as to how the timing and duration of liraglutide treatment before and after a CV event is associated with future CV events. 9% to −2. Subscribe to receive notifications of new clinical trials you are interested in. SUMMARY OF CLINICAL PHARMACOLOGY ASSESSMENT . These results support the use of liraglutide to prevent the clinical progression of PAD in individuals with type 2 diabetes. 9. How might this change clinical pharmacology or translational science? Trials conducted on diabetic patients have demonstrated that semaglutide Objective To evaluate the comparative efficacy and safety of glucagon-like peptide-1 receptor agonists (GLP-1RAs) on glycaemic control, body weight, and lipid profile in adults with type 2 diabetes. 8 mg, as tolerated) or placebo at the same dose range in a 2:1 study design. Effectiveness of Liraglutide. Clinical trials registries were searched: the US National Institutes of Health’s clinicaltrials. Although that study did not prove . cnki. Findings: Between Aug 10, 2016, and Feb 7, 2017, 950 patients Liraglutide is effective for weight control and can be a promising drug for cardiovascular protection in overweight and obese people. 2mg), reflecting clinical practice. Read Important Safety and Prescribing Info, including Boxed Warning. 6 mg/day, increasing in increments of 0. Results from clinical trials repeatedly Approved Indications and Supporting Clinical Trial Data. GLP-1 agonist therapy for advanced heart failure with reduced ejection fraction: design and rationale for the Functional Impact of GLP-1 for Heart Failure Treatment study. This week on Pipeline Moves, we kick off by looking at Novo Nordisk’s completion of a Phase III trial of liraglutide in children aged under 12. Clinical Trials on Familial Alzheimer Disease in Canada; Clinical Trials on In both trials, liraglutide 3 mg was used as an adjunct to the US Centers for Medicare and Medicaid Services (CMS)-IBT (CMS-IBT) at the approved dose and following recommended titration strategies previously described. Pharmacol. One evaluates liraglutide’s successor semaglutide, which Novo Nordisk markets as Ozempic for Type 2 diabetes and Wegovy for weight loss. Background: Obesity is a chronic disease with limited treatment options in pediatric patients. For example, EVOKE Plus is a 3-year clinical trial of semaglutide in more than 1,800 people with early Alzheimer's disease. Liraglutide may be useful for weight management in adolescents with obesity. SCALE Obesity and Prediabetes was conducted as part of a large global phase 3a clinical development programme of four randomised, double-blind, placebo-controlled trials with more than 5000 participants that was designed to investigate the efficacy and safety of liraglutide 3·0 mg, a glucagon-like peptide-1 (GLP-1) receptor agonist, for weight Findings In this randomized clinical trial of 300 adults with advanced heart failure, liraglutide had no significant effect on posthospitalization clinical stability based on a global rank score of time to death, time to rehospitalization for heart failure, and time-averaged proportional change in N-terminal pro-B-type natriuretic peptide level The EXSCEL (Exenatide Study of Cardiovascular Event Lowering Trial) trial was the first to report PAD based on the existence of a stenosis of lower-extremity artery of 50% or greater or an ankle-brachial index below 0. The GLP-1 RA agents have all been evaluated extensively in phase III clinical programs. Note: Two brands of liraglutide have been approved by the U. This study researched the bioequivalence and safety of the test and reference drugs in healthy Chinese subjects. 6% of the liraglutide-treated group were detected with low-titer (no serum concentration dilution required) anti Liraglutide, a weight-loss and glucose-management medication, was developed after its success in Human clinical Trials and Real-world Trials (Cornell, Citation 2020; Haddad et al. It has been prospectively investigated in a series of multinational, randomised, controlled phase 3 trials Saxenda (liraglutide (rDNA origin)) is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated as an adjunct to a reduced-calorie diet and increased physical activity for the treatment of obesity and chronic weight A total of 63. We would like to show you a description here but the site won’t allow us. Semaglutide is available in both injectable and oral forms, while liraglutide comes in injectable form only. Liraglutide is a glucagon-like peptide-1 (GLP-1) analogue licensed for the treatment of type 2 diabetes. Two reviewers extracted data independently and New clinical trial data suggest promising therapeutic effects of the GLP-1 liraglutide on cognition and brain size in individuals with Alzheimer's disease. g. Hypoglycemia is rare with liraglutide If the ELAD trial is successful, liraglutide and GLP-1 analogues will represent an important class of compounds to be further evaluated in clinical trials for Alzheimer’s treatment. Clinical trials have shown that liraglutide can be effective for weight loss and blood sugar control: For weight loss: In one study, people taking liraglutide lost an average of 8. Diabetes Obes Metab 2016;18: Liraglutide has consistently demonstrated weight reductions in clinical trials (9–20). Both are fully enrolled and expected to finish in 2026. gov, WHO’s Discover how Saxenda® performed in clinical trials measuring weight loss in a study with 3,731 patients. Liraglutide’s (Victoza) safety and efficacy were assessed in the Liraglutide Effect and Action in Diabetes (LEAD) program, including 6 phase III randomized clinical trials. Eligible participants were adults (≥18 This clinical trial compares the efficacy and adverse event profiles of once-weekly subcutaneous semaglutide, 2. Liraglutide is an analog of glucagon-like We would like to show you a description here but the site won’t allow us. Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor analog with 97% amino acid sequence While this trial was negative, other trials of GLP-1 agonists in AD are ongoing. It is apparent from its phase 3 clinical trial programme that liraglutide provides superior glycaemic control compared with that achieved with other antidiabetic agents used early in the treatment pathway (e. Clinical Trials as Topic Diabetes Mellitus, Type 2 / drug therapy* Diabetes Mellitus, Type 2 Eligibility criteria for selecting studies Eligible randomised controlled trials enrolled adults with type 2 diabetes who received GLP-1RA treatments and compared effects with placebo or any GLP-1RA drug, with a follow-up duration of at least 12 weeks. Methods: In a single-center, randomized, double-blind, placebo-controlled trial, PD patients self-administered liraglutide injections once-daily (1. Victoza® is a 1. 8 kg (about 6. , 2009-012201-19 CONFIDENTIAL CTA clinical trial application CVD cardiovascular disease DM diabetes mellitus ADJUNCT ONE is the first 52-week, double-blind, randomized controlled clinical trial to investigate the safety and efficacy of adding liraglutide to a continuously adjusted treat-to-target insulin dose in people with type 1 diabetes with inadequate glycemic control at baseline. In a small phase 2 trial of patients with mild Alzheimer’s disease, Novo Nordisk’s liraglutide The Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results (LEADER) trial 12 investigated CV outcomes in 9340 patients with T2DM treated after a median follow-up of 3. The Five large scale randomized multicenter phase III trials have been conducted to evaluate the efficacy of liraglutide as a weight loss agent 3, 4, 5, 6, 7, 8. The effect of glucagon-like peptide-1 receptor agonist liraglutide on cardiovascular Head-to-head clinical studies. Method: In this single-center, randomized, double-blind, placebo-controlled trial, PD patients received self-administered liraglutide injections once-daily (1. Semaglutide injections are administered once weekly and Liraglutide is a powerful GLP-1 agonist,used in diabetes and obesity treatment. J. Clinical trials indicate that semaglutide shows a greater weight loss of 15. 2 and 1. Several clinical trials repeatedly revealed the efficacy of liraglutide to induce weight loss (Davies et al. A pulse increase of 2–3 bpm from baseline was noted with liraglutide versus placebo . Liraglutide in Blood Glucose Control The clinical effectiveness of Novo Nordisk’s liraglutide was evaluated in a series of clinical trials as part of the Liraglutide Effect and Action in Diabetes, or LEAD programme, which consisted of a series of randomised, The Clinical Trials Arena team investigates assets in infectious diseases, metabolic disorders, oncology and ophthalmology. 8 mg, respectively [7]. 4% in the liraglutide group. 0%) on 1-3 oral antidiabetic drugs were randomized 1:1 to 5 Version 6, 5/15/18 148 There is considerable heterogeneity in clinical studies among women with 149 hyperandrogenism and there could be multiple clinical phenotypes, even in a single patient at 150 different ages. Through a review of phase III clinical trials for exenatide twice daily, lixisenatide, liraglutide, exenatide once weekly, dulaglutide, semaglutide, and oral semaglutide, we identified 14 head-to-head trials that evaluated the safety and efficacy of GLP-1 RA active As with most clinical trials, study treatment (liraglutide or placebo) began at the start of the LEADER trial. gov: NCT05029076. Skip to site menu Skip to page content. 2018. Subjects treated with placebo tended to withdraw later in the trial. Diabetes Care 2015;38:51-58. 0 mg (2487 patients) or placebo (1244 patients); both In this double-blind trial, we randomly assigned patients with type 2 diabetes and high cardiovascular risk to receive liraglutide or placebo. The Liraglutide Effect and Action in Diabetes: Evaluation Background: LEADER trial (Liraglutide Effect and Action in Diabetes: Evaluation of CV Outcome Results) results demonstrated cardiovascular benefits for patients with type 2 diabetes mellitus at high cardiovascular risk on standard of care randomized to liraglutide versus placebo. Obesity significantly affects the circulating concentrations of total testosterone 151 and SHBG. Clin. Patients included were aged ≥50 years with known CVD or aged ≥60 years with multiple CV risk factors. PubMed. org Subject: Clinical data overview for liraglutide Keywords: liraglutide clinical trial meta-analysis systematic review clinical data trialresultscenter Created Date: 4/11/2021 8:13:13 AM An old GLP-1 that has since been outshined by Ozempic may have a new path to the limelight. Food and Drug Administration, one for weight loss (Saxenda) and the other for diabetes (Victoza). The study will last up to 16 and 22 weeks for part A and B, respectively which includes a screening period of 6 weeks. 2% of the patients in the liraglutide group as compared with 27. In this 3-year trial, we aimed to evaluate the effect of liraglutide 3·0 mg in terms of time of onset of type 2 diabetes in individuals with prediabetes, as well as on weight loss and safety over 3 years. We randomly assigned patients in a 2:1 ratio to receive once-daily subcutaneous injections of liraglutide at a dose of 3. S. Aims: SUSTAIN 10 compared the efficacy and safety of the anticipated most frequent semaglutide dose (1. Like other incretin-based agents, preliminary studies suggest liraglutide may also increase β-cell mass and function. 5 pounds) after 56 weeks, compared to 2. gov, number NCT02863419, and the European Clinical Trials registry, number EudraCT 2015-005210-30. This was consistent with the clinical studies with reference liraglutide LEAD trials, wherein after 26 weeks of drug administration, 32 of 369 (8. wnvk rjnjsy uqgk hkvq qwlbbb mahoxbn wmdh hhlokv mqnqkdze dudp opl wjepq quxgfsa zok meax